Spots Global Cancer Trial Database for bicalutamide
Every month we try and update this database with for bicalutamide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | NCT01120236 | Prostate Adenoc... Recurrent Prost... Stage IV Prosta... | Bicalutamide Cixutumumab Goserelin Aceta... Laboratory Biom... Leuprolide Acet... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| RAD001 and Bicalutamide for Androgen Independent Prostate Cancer | NCT00630344 | Prostate Cancer | RAD001 Bicalutamide | 18 Years - | Dana-Farber Cancer Institute | |
| Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery) | NCT02742675 | Prostate Cancer | Bicalutamide goserelin aceta... flutamide leuprolide acet... triptorelin Definitive Trea... | 18 Years - 80 Years | Fudan University | |
| Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery) | NCT02742675 | Prostate Cancer | Bicalutamide goserelin aceta... flutamide leuprolide acet... triptorelin Definitive Trea... | 18 Years - 80 Years | Fudan University | |
| Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer | NCT05095207 | Breast Cancer Metastasis | Abemaciclib Bicalutamide | 18 Years - 90 Years | Icahn School of Medicine at Mount Sinai | |
| Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer | NCT01050842 | Prostate Cancer Adenocarcinoma ... Hormone-resista... Stage IV Prosta... | bicalutamide raloxifene quality-of-life... | 18 Years - | Mayo Clinic | |
| Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer | NCT00657904 | Non-metastatic ... | Bicalutamide Placebo | 18 Years - | AstraZeneca | |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score | NCT05050084 | Prostate Adenoc... | Bicalutamide Buserelin Darolutamide Degarelix Flutamide Goserelin Histrelin Leuprolide Radiation Thera... Relugolix Triptorelin | 18 Years - | NRG Oncology | |
| Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | NCT01120236 | Prostate Adenoc... Recurrent Prost... Stage IV Prosta... | Bicalutamide Cixutumumab Goserelin Aceta... Laboratory Biom... Leuprolide Acet... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer | NCT01342367 | Prostate Cancer | Bicalutamide Dutasteride Finasteride Radiation | 18 Years - | University of Chicago | |
| A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer | NCT03520478 | Prostate Cancer Hormone-Depende... | SHR3680 Bicalutamide | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer | NCT02910050 | Breast Cancer | Bicalutamide Aromatase Inhib... | 18 Years - 80 Years | Sun Yat-sen University | |
| Casodex - Nolvadex Combination | NCT00637871 | Gynaecomastia Prostate Cancer | Casodex Tamoxifen | - | AstraZeneca | |
| Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum | NCT00012090 | Fallopian Tube ... Ovarian Cancer Primary Periton... | bicalutamide goserelin aceta... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase II Dutasteride in Combination With CAB vs CAB in SDC | NCT05513365 | Salivary Duct C... | Goserelin 10.8 ... Bicalutamide 50... Dutasteride 0.5... | 18 Years - | Radboud University Medical Center | |
| Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy | NCT00086736 | Prostate Cancer | bicalutamide eflornithine oral eflornithi... oral bicalutami... | 18 Years - | University of Alabama at Birmingham | |
| Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer | NCT00833248 | Prostate Cancer | Degarelix Goserelin Bicalutamide | 18 Years - | Ferring Pharmaceuticals | |
| S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer | NCT00028769 | Prostate Cancer | bicalutamide estramustine etoposide flutamide goserelin leuprolide nilutamide paclitaxel | 18 Years - | SWOG Cancer Research Network | |
| Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients | NCT03650894 | Breast Neoplasm... Breast Cancer Breast Carcinom... Breast Tumor | Nivolumab Ipilimumab Bicalutamide | 18 Years - | Providence Health & Services | |
| Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer | NCT00244920 | Prostate Cancer | bicalutamide leuprolide acet... squalamine lact... adjuvant therap... antiandrogen th... antiangiogenesi... conventional su... neoadjuvant the... releasing hormo... | 18 Years - | OHSU Knight Cancer Institute | |
| Hormone Therapy in Treating Patients With Advanced Prostate Cancer | NCT00003026 | Prostate Cancer | bicalutamide flutamide triptorelin radiation thera... | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer | NCT00521781 | Prostatic Neopl... | Abraxane Leuprolide Bicalutamide | 18 Years - | The Methodist Hospital Research Institute | |
| CMAB vs IMAB in Metastatic Prostate Cancer | NCT00255268 | Metastatic Pros... | Goserelin Bicalutamide | 18 Years - | AstraZeneca | |
| Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy | NCT00086736 | Prostate Cancer | bicalutamide eflornithine oral eflornithi... oral bicalutami... | 18 Years - | University of Alabama at Birmingham | |
| A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer | NCT01288911 | Prostatic Neopl... | enzalutamide bicalutamide | 18 Years - | Astellas Pharma Inc | |
| Positive Surgical Margins Rate and EGFR Family Members Expression in Prostate Cancer Treated With Bicalutamide | NCT00421694 | Prostate Cancer | Bicalutamide | 18 Years - 75 Years | University of L'Aquila | |
| Clinical Trial to Study Quality of Life in Prostate Cancer Patients by Randomizing Anti-androgen Versus Total Androgen Blockage Prior to Curative Intended Radiation Therapy | NCT02382094 | Prostate Cancer | Bicalutamide | - | Karolinska University Hospital | |
| External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer | NCT00388804 | Prostate Cancer | Radiation Thera... Bicalutamide Leuprolide Goserelin Flutamide Questionnaire | - | M.D. Anderson Cancer Center | |
| Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer | NCT00631527 | Prostate Cancer | Leuprolide Goserelin Sunitinib Malat... Casodex Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer | NCT00659438 | Prostate Cancer | ZD6474 (Vandeta... Bicalutamide Placebo | 18 Years - | Sanofi | |
| Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | NCT00170157 | Prostate Adenoc... Prostate Carcin... Recurrent Prost... Stage III Prost... Stage IV Prosta... | Bicalutamide Flutamide Goserelin Aceta... Ipilimumab Leuprolide Acet... Pharmacological... | 18 Years - | Mayo Clinic | |
| Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | NCT03147196 | Stage I Prostat... Stage II Prosta... | Bicalutamide Laboratory Biom... Questionnaire A... Raloxifene Hydr... | 40 Years - | Mayo Clinic | |
| Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer | NCT00771017 | Prostate Cancer | GVAX prostate c... bicalutamide goserelin leuprolide acet... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer | NCT01809691 | Prostate Cancer | TAK-700 Bicalutamide | 18 Years - | SWOG Cancer Research Network | |
| SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer | NCT00026377 | Prostate Cancer | bicalutamide flutamide goserelin aceta... leuprolide acet... SU5416 radiation thera... | - | University of Chicago | |
| Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer | NCT00651326 | Prostate Cancer | bicalutamide buserelin flutamide goserelin leuprolide acet... neoadjuvant the... quality-of-life... radiation thera... Docetaxel | 18 Years - | Canadian Cancer Trials Group | |
| Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer | NCT01342367 | Prostate Cancer | Bicalutamide Dutasteride Finasteride Radiation | 18 Years - | University of Chicago | |
| Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS） | NCT05087706 | Salivary Gland ... | Pyrotinib Bicalutamide Leuprorelin | 18 Years - | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer | NCT00771017 | Prostate Cancer | GVAX prostate c... bicalutamide goserelin leuprolide acet... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer | NCT01786265 | Prostate Adenoc... Recurrent Prost... | Abiraterone Ace... Bicalutamide Degarelix Flutamide Goserelin Aceta... Leuprolide Acet... Nilutamide Prednisone | 18 Years - | M.D. Anderson Cancer Center | |
| SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer | NCT00002651 | Prostate Cancer | bicalutamide goserelin aceta... clinical observ... | 18 Years - | SWOG Cancer Research Network | |
| Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration | NCT00878436 | Prostate Cancer Prostatic Neopl... | Panobinostat Bicalutamide | 18 Years - | NYU Langone Health | |
| Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle | NCT00586898 | Prostate Cancer Hormonal Cyclin... | GnRH Ketoconazole Bicalutamide Testosterone tr... Estrogen transd... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | NCT02299999 | Metastatic Brea... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Bicalutamide Olaparib Anthracyclines Taxanes cyclophosphamid... DNA intercalato... Methotrexate vinca alkaloids Platinum based ... Bevacizumab Mitomycin C Eribulin MEDI4736 | 18 Years - | UNICANCER | |
| Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy | NCT00776594 | Prostate Cancer | Androgen Depriv... bicalutamide bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy | NCT00850941 | Prostate Cancer | Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer | NCT02058706 | Adenocarcinoma ... Recurrent Prost... Stage IV Prosta... | enzalutamide bicalutamide orchiectomy leuprolide acet... goserelin aceta... laboratory biom... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum | NCT00012090 | Fallopian Tube ... Ovarian Cancer Primary Periton... | bicalutamide goserelin aceta... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| RAD001 and Bicalutamide for Androgen Independent Prostate Cancer | NCT00630344 | Prostate Cancer | RAD001 Bicalutamide | 18 Years - | Dana-Farber Cancer Institute | |
| Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer | NCT00589472 | Prostate Adenoc... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... | Bicalutamide Goserelin Aceta... Laboratory Biom... Leuprolide Acet... Therapeutic Con... Vorinostat | 19 Years - | National Cancer Institute (NCI) | |
| A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery | NCT03809000 | Prostate Cancer | Radiation Thera... Enzalutamide Bicalutamide GnRH analog | 18 Years - | RTOG Foundation, Inc. | |
| Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy | NCT00002874 | Prostate Cancer | bicalutamide radiation thera... placebo | - | Radiation Therapy Oncology Group | |
| A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy | NCT03043807 | Prostate Cancer | Leuprolide Acet... Docetaxel Bicalutamide Radiation Abiraterone Ace... | 18 Years - 80 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration | NCT00878436 | Prostate Cancer Prostatic Neopl... | Panobinostat Bicalutamide | 18 Years - | NYU Langone Health | |
| Survival Outcomes and Tumor Molecular Profile Following Bicalutamide Neoadjuvant Therapy | NCT00418080 | Prostate Cancer | bicalutamide | 18 Years - 75 Years | University of L'Aquila | |
| Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy | NCT00528866 | Prostate Cancer | bicalutamide docetaxel flutamide LHRH agonist 3-dimensional c... radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
| Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer | NCT00769795 | Prostate Cancer | IMC-A12 Bicalutamide Goserelin | 18 Years - | University of Washington | |
| Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer | NCT02615223 | Stage IV Prosta... | cryoablation Bicalutamide luteinizing-hor... | 18 Years - 80 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer | NCT00589472 | Prostate Adenoc... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... | Bicalutamide Goserelin Aceta... Laboratory Biom... Leuprolide Acet... Therapeutic Con... Vorinostat | 19 Years - | National Cancer Institute (NCI) | |
| Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer | NCT00658697 | Prostate Cancer | Docetaxel Bevacizumab ADT Bicalutamide | 18 Years - | Dana-Farber Cancer Institute | |
| Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide | NCT00871585 | Advanced Prosta... | 40 Years - | AstraZeneca | ||
| Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer | NCT00003653 | Prostate Cancer | bicalutamide buserelin cyproterone ace... flutamide goserelin leuprolide acet... nilutamide | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer | NCT00657904 | Non-metastatic ... | Bicalutamide Placebo | 18 Years - | AstraZeneca | |
| A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer | NCT05327647 | Non-Muscle Inva... | Bicalutamide Control Arm | 18 Years - | CHU de Quebec-Universite Laval | |
| Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer | NCT00004054 | Prostate Cancer | bicalutamide estramustine ph... etoposide flutamide paclitaxel Luteinizing hor... Radiation thera... warfarin | 18 Years - | Radiation Therapy Oncology Group | |
| Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients | NCT02348281 | Breast Cancer | Bicalutamide | 18 Years - 70 Years | Fudan University | |
| Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer | NCT01251861 | Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... | Akt Inhibitor M... Bicalutamide Clinical Observ... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Phase II Dutasteride in Combination With CAB vs CAB in SDC | NCT05513365 | Salivary Duct C... | Goserelin 10.8 ... Bicalutamide 50... Dutasteride 0.5... | 18 Years - | Radboud University Medical Center | |
| Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer | NCT00846976 | Prostate Cancer | Bicalutamide | 18 Years - | AstraZeneca | |
| Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer | NCT00512668 | Adenocarcinoma ... Recurrent Prost... | leuprolide acet... goserelin aceta... bicalutamide nilutamide flutamide temsirolimus laboratory biom... | - | National Cancer Institute (NCI) | |
| Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy | NCT00470834 | Neoplasms, Pros... | dutasteride placebo bicalutamide | 40 Years - 90 Years | GlaxoSmithKline | |
| Hormone Therapy in Treating Patients With Advanced Prostate Cancer | NCT00003026 | Prostate Cancer | bicalutamide flutamide triptorelin radiation thera... | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509) | NCT03141671 | Prostate Cancer | GnRH Bicalutamide Salvage radiati... Abiraterone Prednisone Apalutamide | 18 Years - 95 Years | Dana-Farber Cancer Institute | |
| Bicalutamide Monotherapy Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer | NCT00551044 | Prostatic Neopl... | Bicalutamide | - | Wirral University Teaching Hospital NHS Trust | |
| A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer | NCT03009981 | Prostate Cancer | Apalutamide LHRH Analogue Abiraterone Ace... Prednisone | 18 Years - | Alliance Foundation Trials, LLC. | |
| Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients | NCT00884273 | Prostate Cancer | Degarelix Goserelin Bicalutamide | 18 Years - | Ferring Pharmaceuticals | |
| TAK-700 in Castration Resistant Prostate Cancer | NCT01658527 | Prostate Cancer | Orteronel Bicalutamide | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| TAK-700 in Castration Resistant Prostate Cancer | NCT01658527 | Prostate Cancer | Orteronel Bicalutamide | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer | NCT00936390 | Prostate Cancer | bicalutamide flutamide LHRH agonist (a... Dose-Escalated ... | 18 Years - | Radiation Therapy Oncology Group | |
| AR-inhibitor Bicalutamide in Treating Patients With TNBC | NCT02353988 | Breast Neoplasm... | Bicalutamide Physician's Cho... | 18 Years - 70 Years | Jinling Hospital, China |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
